Cyclophosphamide and Robitussin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cyclophosphamide and Robitussin. Common interactions include pneumonia among females and arteriovenous fistula occlusion among males.

The phase IV clinical study analyzes what interactions people who take Cyclophosphamide and Robitussin have. It is created by eHealthMe based on reports of 34 people who take Cyclophosphamide and Robitussin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 26, 2023

34 people who take Cyclophosphamide and Robitussin together, and have interactions are studied.

What is Cyclophosphamide?

Cyclophosphamide has active ingredients of cyclophosphamide. It is often used in multiple myeloma. eHealthMe is studying from 149,590 Cyclophosphamide users for its effectiveness, alternative drugs and more.

What is Robitussin?

Robitussin has active ingredients of guaifenesin. eHealthMe is studying from 3,062 Robitussin users for its effectiveness, alternative drugs and more.

Number of Cyclophosphamide and Robitussin reports submitted per year:

Common Cyclophosphamide and Robitussin drug interactions by gender *:

female:

Pneumonia
Febrile neutropenia
Pyrexia
Cough
Dyspnoea
Lymphoedema
Muscle spasms
Encephalopathy
Septic shock
Anal pruritus

male:

Arteriovenous fistula occlusion
Febrile neutropenia
Renal failure
Diarrhoea
Epistaxis
Gingival bleeding
Haematochezia
Rhinorrhoea
Upper respiratory tract infection
Asthma

Common Cyclophosphamide and Robitussin drug interactions by age *:

0-1:

n/a

2-9:

Febrile neutropenia
Diarrhoea
Epistaxis
Gingival bleeding
Haematochezia
Rhinorrhoea
Upper respiratory tract infection

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Abdominal pain
Cough
Hypophagia
Neutropenia
Oropharyngeal pain
Pneumonia
Pyrexia
Sinusitis

50-59:

Anaemia
Arteriovenous fistula occlusion
Dyspnoea
Arthralgia
Blood pressure increased
Bronchiectasis
Chronic kidney disease
Cough
Febrile neutropenia
Lymphoedema

60+:

Pneumonia
Febrile neutropenia
Hypogammaglobulinaemia
Septic shock
Anal pruritus
Back pain
Bone pain
Constipation
Cough
Death

Common conditions people have *:

Cough: 7 people, 20.59%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 7 people, 20.59%
Bone Marrow Conditioning Regimen: 7 people, 20.59%
Febrile Neutropenia (fever with reduced white blood cells): 6 people, 17.65%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 14.71%
High Blood Pressure: 4 people, 11.76%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 8.82%
Chest Pain: 3 people, 8.82%
Anaemia (lack of blood): 2 people, 5.88%
Breast Cancer: 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Cyclophosphamide and Robitussin?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .